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Abstract Patients with rheumatoid arthritis (RA) are at an
increased risk of cardiovascular disease (CVD). Treatment
with tumor necrosis factor inhibitors improves both joint
symptoms associated with RA and also CVD risk. This ex-
ploratory analysis of a phase 4 study evaluated changes in
metabolic risk factors in patients with RA treated with
etanercept. Metabolic analytes were measured at baseline,
week 12, and week 24 in patients enrolled in a randomized,
double-blind, placebo-controlled study to evaluate the effica-
cy and safety of etanercept in moderately active RA. Patients
received either placebo or etanercept 50 mg every week (QW)
for 12 weeks, after which all patients received etanercept
50 mg QW through week 24. Levels of metabolic analytes
were assessed in all patients, including patients with diabetes
and hyperlipidemia, and described descriptively. A total of
210 patients were randomized, 104 to placebo and 106 to
etanercept. There were no significant changes in metabolic
risk factors from baseline to week 12 or 24 in all patients.
Levels of metabolic analytes were similar in patients with
diabetes and hyperlipidemia, with some exceptions; fasting
glucose and fasting insulin decreased through week 12, and
hemoglobin A1C decreased slightly through week 24 in pa-
tients with diabetes. Treatment with etanercept did not ad-
versely affect levels of metabolic risk factors for CVD in pa-
tients with RA.
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Introduction
It is well documented that patients with rheumatoid arthritis
(RA) are at an increased risk of cardiovascular disease (CVD)
and experience higher rates of cardiovascular (CV) morbidity
and mortality than the general population [1–4]. While tradi-
tional CVD risk factors—including cholesterol levels—may
contribute to this heightened risk in patients with RA, they do
not completely account for the increased incidence of CV
events [5, 6]. In addition to traditional CVD risk factors, the
systemic inflammation associated with RA also plays a role in
increasing CVD risk in patients [7]. Decreasing inflammation
is thought to decrease CV morbidity and mortality in patients
with RA [8]. Tumor necrosis factor inhibitor (TNFi) therapy,
in particular, has been shown to improve both RA symptoms
and CVD risk and reduce CV morbidity and mortality [9, 10].
In this study, we measured the levels of selected metabolic
analytes in patients with RA who received treatment with
etanercept to further understand the effect of TNFi therapy
on traditional CVD risk factors.
Materials and methods
Study design
The evaluation of CVD risk factors was an exploratory end-
point in a phase 4, prospective, randomized, double-blind,
placebo-controlled study (NCT01313208) to evaluate the ef-
ficacy and safety of etanercept in patients with moderately
active RA despite disease-modifying anti-rheumatic drug
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(DMARD) therapy. Patients were randomized 1:1 to receive
50 mg etanercept or placebo every week (QW) for 12 weeks,
stratified by current methotrexate (MTX) use (yes/no). At
week 12, all patients received 50 mg etanercept QW for an-
other 12 weeks.
Patients
Eligibility criteria have been previously published [11]. In
particular, patients were required to have moderately active
RA, as defined by their disease activity score based on 28
joints (DAS28) with C-reactive protein (CRP) as the indicator
of inflammation (3.2 < DAS28-CRP ≤ 5.1).
Subpopulations of interest
Patients were further categorized based on diabetes and hy-
perlipidemia. Patients with diabetes were defined as those
with a current history of diabetes (stop date in medical history
missing or after enrollment date), and/or taking insulin, and/or
taking oral anti-diabetics. Patients with hyperlipidemia were
defined as those with a current history of hyperlipidemia or
hypercholesterolemia (stop date in medical history missing or
after enrollment date) and/or taking statins.
Objective
The objective of this study was to evaluate changes in meta-
bolic CVD risk factors in patients with moderately active RA
treated with etanercept.
Outcomes
The metabolic analytes measured in this study were fasting
glucose, fasting insulin, hemoglobin A1C, total cholesterol,
high-density lipoprotein (HDL), low-density lipoprotein
(LDL), triglycerides, apolipoprotein A1, apolipoprotein B,
adiponectin, leptin, and plasma N-terminal pro b-type natri-
uretic peptide (NT-proBNP). Shifts in grade (low, normal,
high) for each analyte from baseline to week 24 were also
measured.
Statistical analyses
Baseline demographics, disease characteristics, and metabolic
parameters were summarized descriptively for the overall
study population and diabetic and hyperlipidemic subpopula-
tions by treatment groups and time points. Changes in meta-
bolic parameters over time during the study are also displayed
graphically.
Human rights
The study protocol and informed consent form were approved
by the applicable Independent Ethics Committee (IEC) or
Institutional Review Board (IRB). Patients were informed of
all aspects of the study, and the forms were obtained before
patients entered the study.
Results
Demographic and clinical characteristics at baseline
A total of 210 patients were enrolled in this study. During the
first 12 weeks, 104 patients were randomized to placebo and
106 patients were randomized to etanercept (Table 1). The
double-blind phase was completed by 95 % of patients:
94 % placebo and 95 % etanercept (Fig. 1). The open-label
phase was completed by 91 % of patients: 89 % placebo-
etanercept and 93 % etanercept-etanercept. Overall, the pa-
tients had a mean (standard deviation [SD]) age of 56 (12)
years, were 77 % female, were 87 % white, had a mean (SD)
RA duration of 8 (10) years, and had a mean (SD) disease
severity (as measured by DAS28-CRP) of 4.9 (0.8)
(Table 1). There were 14 % of patients with a medical history
of diabetes and 30% with a medical history of hyperlipidemia
or hypercholesterolemia. There were 22 % of patients receiv-
ing statins, 11 % anti-diabetic oral agents, 3 % insulin, and
52 % prednisone.
Changes in metabolic analytes
Levels of CRP decreased in the overall study population by
week 24, but there were no significant changes in any other
metabolic analytes measured from baseline to weeks 12 and
24 in all patients (Table 2). There were rare elevations in liver
function tests and none greater than three times normal.
The metabolic analytes in patients with diabetes and hyper-
lipidemia did not change substantially from baseline to week
12 or 24 and were similar to those in the total study popula-
tion, with some exceptions (Table 2 and Fig. 2). In patients
with diabetes, fasting glucose decreased, HDL increased, and
LDL decreased throughweek 12 in those receiving etanercept.
In both subpopulations, fasting insulin decreased through
week 12 and hemoglobin A1C decreased slightly through
week 24. In addition, apolipoprotein A1 increased (with the
exception of patients with diabetes receiving placebo-
etanercept) and adiponectin increased slightly through week
24; leptin and apolipoprotein B did not change. Patients at a
higher CVD risk experienced no or minimal changes in met-
abolic analytes from baseline to weeks 12 and 24. All changes
that patients did experience were neither statistically nor clin-
ically significant. Metabolic analytes were also compared
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between patients receiving concurrent nonsteroidal anti-
inflammatory drugs and those who were not, among the total
study population, patients with diabetes, and patients with
hyperlipidemia; responses were similar between groups (data
not shown).
Shifts in grade for analytes
For the majority of patients, all metabolic analytes were in the
normal range at baseline. The majority of patients completed
the study week 24 at a normal grade for each analyte mea-
sured. Fewer than 25 % of patients in either treatment group
experienced a shift in grade between baseline and week 24 for
each metabolic analyte measured. Among those who did ex-
perience a shift in grade, patients were fairly evenly divided
between those who improved in grade and those who
worsened.
Discussion
Treatment with etanercept did not adversely or positively af-
fect the levels of traditional metabolic CVD risk factors in
patients with RA. There were no significant changes in these
metabolic analytes despite improvements in RA activity pa-
rameters, as indicated by decreases in CRP in both groups on
etanercept by week 24. Previously reported improvements in
CVD risk associated with TNFi therapy may stem from
changes in other factors such as decrease in systemic inflam-
mation. Results seen in patients with diabetes and
Table 1 Demographic and
clinical characteristics at baseline Characteristic Placebo-etanercept Etanercept-etanercept Total
n = 104 n = 106 n = 210
Sex (female), n (%) 86 (82.7) 75 (70.8) 161 (76.7)
Race (white), n (%) 90 (86.5) 93 (87.7) 183 (87.1)
Age (years), mean (SD) 55.5 (12.8) 56.5 (12.1) 56.0 (12.4)
DAS28-CRP, mean (SD) 4.9 (0.8) 4.9 (0.7) 4.9 (0.8)
CRP (mg/L), mean (SD) 9.4 (16.3) 7.6 (11.8) 8.5 (14.2)
ESR (mm/h), mean (SD) 30.8 (23.5) 30.3 (22.8) 30.6 (23.1)
Tobacco, n (%)
Never 49 (47.1) 54 (50.9) 103 (49.0)
Former 35 (33.7) 34 (32.1) 69 (32.9)
Current 20 (19.2) 18 (17.0) 38 (18.1)
RA duration (years), mean (SD) 7.4 (8.1) 8.3 (11.2) 7.8 (9.8)
RA medication history, n (%) 103 (99.0) 106 (100.0) 209 (99.5)
DMARDs (nonbiologic) 103 (99.0) 105 (99.1) 208 (99.0)
NSAIDs 70 (67.3) 75 (70.8) 145 (69.0)
Corticosteroids 68 (65.4) 73 (68.9) 141 (67.1)
Analgesics 44 (42.3) 38 (35.8) 82 (39.0)
Biologics 10 (9.6) 10 (9.4) 20 (9.5)
Other 1 (1.0) 0 (0.0) 1 (0.5)
Type 2 diabetes mellitusa, n (%) 12 (11.5) 17 (16.0) 29 (13.8)
Hyperlipidemiab, n (%) 30 (28.8) 33 (31.1) 63 (30.0)
Other medication history, n (%)
Statin 21 (20.2) 26 (24.5) 47 (22.4)
Insulin 2 (1.9) 4 (3.8) 6 (2.9)
Oral anti-diabetic 10 (9.6) 12 (11.3) 22 (10.5)
Prednisone 53 (51.0) 57 (53.8) 110 (52.4)
SD standard deviation,DAS28 disease activity score based on 28 joints, CRP C-reactive protein, ESR erythrocyte
sedimentation rate, RA rheumatoid arthritis,DMARD disease-modifying anti-rheumatic drug,NSAID nonsteroidal
anti-inflammatory drug
a Patients with type 2 diabetes mellitus were defined as those with a current history of diabetes (stop date in
medical history missing or after enrollment date), and/or taking insulin, and/or taking oral anti-diabetics
b Patients with hyperlipidemia were defined as those with a current history of hyperlipidemia or hypercholester-
olemia (stop date in medical history missing or after enrollment date) and/or receiving statins
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hyperlipidemia demonstrated that there were no changes in
traditional metabolic CVD risk factors, even in patients who
were at a heightened risk of CVD.
Patients with RA exhibit a lipid paradox, in which patients
with untreated RA have lower total cholesterol, HDL, and
LDL than the general population, in which these lipid param-
eters are conventionally at elevated levels when patients are at
a higher risk for CVD [5, 12, 13]. A potential explanation is
that higher levels of CRP have been shown to decrease levels
of lipids [6]. Elevated levels of CRP have been shown to
independently correlate with increased CVD risk; a previous
study has shown that elevated CRP was associated with an up
to threefold increase in the risk of a heart attack [14].
Treatment to control RA subsequently results in an increase
in total cholesterol, HDL, and LDL, without a concomitant
increase in CVD risk; and in some cases even a decrease in
CVD risk [6, 12, 13, 15, 16]. In our study, patients did not
experience any change in levels of lipids, similar to some
previous studies [15, 17].
Treatment with TNFi therapy, including etanercept, has
been shown to lower CVD risk in patients with RA [18–20].
Based on analyses in this study and others, the reduction in
CVD risk in patients with RA cannot be fully explained by
changes in traditional metabolic risk factors. Managing RA
symptoms and reducing inflammation in these patients
appears to play a key role to decreasing CVD risk [8]. One
study has even shown that the degree to which TNFi therapy
reduces disease activity is proportional to the reduction in
CVD risk [19]. One possible explanation behind the beneficial
effect of TNFi therapy on CVD risk may relate a reduction in
overall inflammation to a reduction in aortic inflammation.
Findings from Maki-Petaja and colleagues demonstrated that
TNFi therapy reduced aortic inflammation in patients with RA
after 8 weeks of treatment, and this effect correlated with a
decrease in aortic stiffness [21]. This study provides further
evidence that the main effect of TNFi therapy is on inflamma-
tion, which can directly decrease inflammation in the aorta,
preventing plaque formation or progression. Similar to reports
on TNFi therapy, other biologics (e.g., interleukin-6 receptor
inhibitor) also worsen the lipid profile with no worsening of
CVD risk [22, 23].
The well-established benefit of TNFi therapy on CVD risk
in patients with RAmay also not be apparent in the short term.
Recent work by Charles-Schoeman and colleagues demon-
strated that patients with early RA in the treatment of early
aggressive rheumatoid arthritis (TEAR) trial experienced in-
creases in lipids (total cholesterol, LDL, and HDL) through
24 weeks of treatment with etanercept; these levels began to
decrease by 48 weeks of treatment, with statistically signifi-
















Excluded (n = 90)
Randomized (n = 210)
Screened for eligibility
(n = 300)
Discontinued study (n = 6)
 Full consent withdrawn (n = 3)
 Adverse event (n = 1)
 Lost to follow-up (n = 1)
 Noncompliance (n = 1)
Discontinued study (n = 5)
 Full consent withdrawn (n = 2)
 Adverse event (n = 2)
 Ineligibility determined (n = 1)
Discontinued study (n = 6)
 Full consent withdrawn (n = 3)
 Adverse event (n = 1)
 Other (n = 2)
Discontinued study (n = 3)
 Full consent withdrawn (n = 1)
 Noncompliance (n = 2)
Randomized to placebo
(n = 104)
Completed double-blind phase 
through week 12 (n = 98)
Completed open-label phase 
through week 24 (n = 92)
Switched to etanercept 50 mg QW 
(n = 98)
Randomized to etanercept 50 mg 
QW
(n = 106)
Completed double-blind phase 
through week 12 (n = 101)
Completed open-label phase 
through week 24 (n = 98)
Continued on etanercept 50 mg 
QW (n = 101)
Fig. 1 Patient disposition. The flow of patients from screening through week 24 of the study. QW every week
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Given this timeline, the time periods evaluated in this manu-
script—12 and 24 weeks—may not have been long enough to
capture the long-term effects of etanercept treatment on met-
abolic risk factors. In addition, the study reported here
recruited patients with moderate RA with mean a DAS28 of
4.9, compared with the patients with early RA in the TEAR
trial who had mean DAS28 ranging from 5.48 to 5.82. The
lack of high disease activity in this study may have had an
Table 2 Summary of analytes in all patients, patients with diabetes, and patients with hyperlipidemia
Analyte, mean (SD) Visit All Diabetes Hyperlipidemia
PBO-ETN ETN-ETN PBO-ETN ETN-ETN PBO-ETN ETN-ETN
n = 104 n = 106 n = 12 n = 17 n = 30 n = 33
Fasting glucose, mg/dL Baseline 99.0 (30.7) 98.6 (30.3) 143.0 (69.2) 142.3 (53.1) 113.8 (46.2) 111.4 (43.5)
Week 12 95.9 (22.3) 97.3 (26.6) 127.3 (42.4) 133.1 (47.1) 104.3 (32.1) 105.9 (29.3)
Week 24 101.0 (22.8) 100.1 (24.0) 134.8 (35.9) 138.4 (35.8) 105.3 (26.0) 107.6 (17.3)
Fasting insulin, mIU/L Baseline 14.3 (17.6) 16.0 (34.9) 24.4 (18.3) 40.3 (79.5) 22.4 (28.5) 26.8 (60.6)
Week 12 15.3 (22.4) 13.2 (13.5) 20.2 (15.0) 16.1 (21.5) 18.0 (16.2) 17.7 (17.3)
Week 24 15.0 (18.4) 12.0 (12.1) 23.0 (22.7) 14.8 (14.0) 14.6 (11.9) 14.4 (12.8)
Hemoglobin A1C, % Baseline 5.7 (0.9) 5.7 (0.7) 7.2 (1.9) 6.7 (1.2) 6.1 (1.4) 6.1 (1.0)
Week 12 5.7 (0.9) 5.6 (0.6) 7.0 (2.1) 6.7 (0.8) 5.9 (1.3) 6.0 (0.8)
Week 24 5.6 (0.9) 5.6 (0.6) 6.8 (1.9) 6.5 (0.8) 5.9 (1.2) 5.8 (0.6)
Total cholesterol, mg/dL Baseline 195.2 (44.2) 186.6 (37.1) 204.0 (32.9) 171.9 (36.6) 205.1 (55.1) 181.6 (42.5)
Week 12 190.9 (40.7) 184.8 (37.4) 205.6 (36.2) 170.0 (33.7) 190.7 (44.2) 182.6 (44.5)
Week 24 197.0 (41.7) 191.1 (39.6) 185.5 (32.4) 179.9 (37.3) 192.8 (44.4) 190.5 (43.2)
HDL, mg/dL Baseline 62.0 (18.1) 62.1 (21.7) 52.6 (13.2) 57.8 (17.1) 57.4 (12.3) 58.5 (18.0)
Week 12 60.5 (17.1) 61.6 (18.3) 54.7 (13.6) 61.9 (19.5) 56.9 (14.0) 61.4 (19.1)
Week 24 62.1 (18.5) 62.2 (22.9) 52.1 (14.5) 60.6 (15.5) 56.0 (13.8) 62.1 (18.4)
LDL, mg/dL Baseline 105.6 (36.3) 97.8 (30.0) 118.4 (26.9) 81.8 (29.5) 109.0 (40.7) 92.7 (37.2)
Week 12 103.2 (35.4) 96.9 (33.2) 112.1 (32.3) 79.3 (31.5) 102.2 (38.2) 90.3 (39.3)
Week 24 105.5 (35.4) 101.7 (31.0) 101.9 (89.1) 89.1 (31.5) 99.0 (34.3) 100.0 (33.3)
Triglycerides, mg/dL Baseline 135.2 (91.6) 133.1 (80.1) 164.7 (68.6) 163.2 (91.6) 183.8 (134.1) 154.2 (78.0)
Week 12 139.2 (85.5) 131.8 (69.4) 221.9 (170.3) 153.8 (71.8) 167.2 (113.4) 155.0 (67.8)
Week 24 149.6 (104.0) 136.6 (76.2) 192.8 (165.2) 150.7 (71.1) 189.8 (141.0) 142.0 (74.9)
Apolipoprotein A1, mg/dL Baseline 159.6 (27.8) 160.5 (35.4) 152.6 (23.2) 158.5 (32.7) 158.9 (26.2) 159.7 (32.8)
Week 12 159.2 (28.1) 162.0 (32.8) 154.8 (25.3) 164.1 (30.3) 157.5 (27.9) 167.8 (34.2)
Week 24 163.7 (32.1) 161.6 (38.0) 150.2 (25.7) 163.5 (22.5) 161.3 (29.8) 167.1 (33.4)
Apolipoprotein B, mg/dL Baseline 91.6 (25.5) 86.2 (22.2) 106.4 (24.1) 79.7 (22.3) 101.7 (28.4) 86.3 (24.5)
Week 12 89.5 (24.7) 84.9 (23.8) 107.3 (25.6) 79.6 (20.7) 95.5 (26.3) 85.8 (25.9)
Week 24 91.8 (24.2) 88.7 (25.0) 91.9 (25.3) 83.5 (22.9) 95.4 (25.2) 91.4 (26.9)
Adiponectin, mg/L Baseline 11.6 (6.8) 11.5 (8.7) 6.8 (3.4) 7.8 (3.8) 9.2 (4.7) 10.5 (8.2)
Week 12 11.7 (7.4) 11.6 (8.8) 7.3 (3.3) 8.4 (4.4) 9.0 (4.4) 10.9 (9.0)
Week 24 12.3 (7.2) 11.6 (9.1) 7.7 (3.7) 8.1 (4.2) 9.7 (4.6) 11.5 (9.6)
Leptin, μg/L Baseline 29.3 (20.9) 33.5 (28.5) 31.5 (23.0) 42.8 (36.6) 33.1 (17.0) 41.5 (30.2)
Week 12 30.1 (22.7) 35.6 (30.9) 30.9 (29.8) 44.1 (31.6) 34.3 (18.8) 43.5 (32.1)
Week 24 30.8 (22.7) 34.5 (28.9) 33.7 (25.7) 39.3 (25.5) 34.1 (22.6) 37.8 (22.8)
Plasma NT-ProBNP, ng/L Baseline 242.0 (554.1) 170.1 (334.6) 242.1 (513.2) 151.0 (153.8) 484.0 (935.9) 210.8 (535.4)
Week 12 232.2 (630.8) 168.2 (297.8) 236.8 (465.8) 114.4 (126.5) 482.8 (1116.5) 158.3 (266.7)
Week 24 244.2 (687.5) 164.2 (315.7) 199.8 (382.8) 157.5 (229.6) 522.4 (1212.0) 174.3 (351.1)
CRP, mg/L Baseline 9.4 (16.3) 7.6 (11.8)
Week 12 8.6 (10.8) 4.2 (6.2)
Week 24 6.2 (14.0) 4.3 (5.5)
SD standard deviation, PBO placebo,ETN etanercept, IU international unit,HDL high-density lipoprotein, LDL low-density lipoprotein,NT-ProBNPN-
terminal pro b-type natriuretic peptide, CRP C-reactive protein
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effect on baseline lipid levels, and the small changes in disease
activity in response to treatment with etanercept may have had
a lesser impact on metabolic parameters. Another possibility
why this study did not show any positive effect of etanercept
on traditional CVD risk factors may be that this study was
underpowered. Larger studies are required to confirm if this
conclusion holds true in different populations.
In managing the CVD risk in patients with RA, it is impor-
tant to evaluate both traditional CVD risk factors and RA
severity. As shown in one study, incorporating both sets of
factors into a model enhances its ability to predict the inci-
dence rate of CVevents [25]. Furthermore, as described in the
European League Against Rheumatism (EULAR) recommen-
dations for CVD risk management in patients with RA, the
control of both systemic inflammation and traditional CVD
risk factors is important to control CVD risk [26, 27]. The
analysis presented here shows that etanercept controls the sys-
temic inflammation in patients with RA, as evidenced by the
reduction of CRP, and does not adversely affect levels of tra-
ditional cardiovascular risk factors.
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